Clinical trials: Prostate Cancer Stage
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate…
- Trial name
- SABRE (NCT05407311)
- Testing
- 64Cu-SAR-BBN
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
This Phase IV observational trial is intended to identify patients who are failing GnRH agonist therapy as evidenced by a rising PSA and who have yet to initiate secondary manoeuvres involving antiandrogens.
- Trial name
- DELAY (NCT01366053)
- Where
- 17 sites in Canada
- Volunteers
- 125 people
- Sponsor
- CMX Research
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone therapy in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02472275
- Testing
- Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of the study drug carlumab in participants with metastatic castrate-resistant prostate cancer (cancer of the gland that makes fluid that aids movement of…
- Trial name
- NCT00992186
- Testing
- Carlumab
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 46 people
- Sponsor
- Centocor Research & Development, Inc.
Risk of Breast Cancer, Risk of Gynaecological Cancer
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease.
- Conditions
- Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers
- Trial name
- LEAH (NCT06907095)
- Testing
- biological samples
- Where
- France
- Volunteers
- 5,909 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Carcinoma
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
- Trial name
- NCT04597359
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Where
- 353 sites in United States, Guam and 1 more
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig…
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Trial name
- NCT05652686
- Testing
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel.
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- Phanes Therapeutics
Metastatic Castration-resistant Prostate Cancer
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC). Participants will be enrolled into one of five cohorts: Cohort 1 (participants with programmed cell death…
- Trial name
- NCT02787005
- Testing
- Pembrolizumab
- Volunteers
- 388 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003394
- Testing
- carboplatin, endocrine-modulating drug therapy, estramustine phosphate sodium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253.
- Trial name
- NCT02987829
- Testing
- TRC253
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Prostate Cancer
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
- Trial name
- NCT00841113
- Testing
- Abarelix, Goserelin plus Bicalutamide
- Volunteers
- 177 people
- Sponsor
- Speciality European Pharma Limited
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the…
- Trial name
- NCT06807359
- Testing
- Photodynamic Therapy (PDT), Verteporfin Injection
- Where
- 3 sites in United States, Germany
- Volunteers
- 43 people
- Sponsor
- SpectraCure AB
Osteoporosis, Prostate Cancer
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more…
- Trial name
- NCT00003903
- Testing
- management of therapy complications
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Rochester
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer.
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT06312670
- Testing
- EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pedro Barata, MD, MSc
Prostate Cancer, Erectile Dysfunction Following Radiation Therapy
EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)
Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the…
- Trial name
- ERECT (NCT04861194)
- Testing
- Neurovascular-sparing
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- UMC Utrecht
Prostate Cancer
Exercise During Active Surveillance for Prostate Cancer
The broad goal of the Exercise During Active Surveillance for Prostate Cancer (ERASE) trial is to examine the effects of exercise in prostate cancer patients undergoing active surveillance.
- Trial name
- ERASE (NCT03203460)
- Testing
- High-intensity aerobic interval training (HIIT)
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University of Alberta
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
The purpose of this study is to compare the effects on prostate cancer using radiation therapy with or without chemotherapy.
- Trial name
- NCT01603420
- Testing
- Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Proton Collaborative Group
Prostate Cancer, Prostate Cancer Recurrent
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04742361
- Testing
- [18F]PSMA-1007
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 136 people
- Sponsor
- ABX advanced biochemical compounds GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.